Press Release: anvajo closes Series A

Dresden-based health tech company anvajo receives EUR 17.7 million in Series A financing round to advance point-of-care diagnostics

According to the motto "Detecting diseases early. Truly point of care", anvajo develops innovative and digital solutions for the analysis of fluids - with a special focus on the healthcare sector. With this business model, the team around CEO Dr Felix Lambrecht was able to raise a total of 17.7 million euros in their Series A financing round. Led by the German pharmaceutical company MEDICE Arzneimittel, other health care specialists invested such as the US fund of Johnsonville Ventures, the German diagnostics specialists Elber Beteiligungen and Think.Health. In addition, the existing investor Die BrückenköpfeX supported the round. The funds will be used to accelerate the launch in human medical markets as well as strengthen the company's existing point of care products.  


anvajo – truly point of care:

The initial idea of founder and CTO Stefan Fraedrich was based on the question of why a multitude of different devices is still necessary for near-patient diagnostics, especially in underserved regions. For this reason, anvajo, a company founded as a spin-off of the Technical University of Dresden, has been working on a platform technology for the prevention, screening, and monitoring of diseases since 2016, initially with a focus on chronic kidney disease.   As a proof-of-concept, anvajo can present the vet fluidlab for urine microscopy, already developed for veterinary medicine, and the fluidlab R-300 for cell counting and spectrometry, developed for research.  


Award-winning technology

Not only did anvajo convince the Series A investors of its goal of offering user-centred and easy-to-use laboratory tests for everyone, everywhere: the company was also one of the award contenders from the health sector in 2022 and was able to secure one of the coveted finalist places in the health-i Awards (Handelsblatt and Techniker Krankenkasse) as well as first place in the Takeda Innovation Challenge (EIT Health Germany).  


Today for the health of tomorrow

anvajo made it it's mission to close the circle between patients, laboratories, and medical professionals. To achieve this goal, the company has brought expert investors on board with the financing round to facilitate access to care and strengthen patient sovereignty through greater health literacy.